Results 141 to 150 of about 12,447 (257)

Monte Carlo Simulation in Environmental Risk Assessment--Science, Policy and Legal Issues [PDF]

, 1998
Dr. Poulter notes that agencies should anticipate judicial requirements for justification of Monte Carlo simulations and, meanwhile, should consider, e.g., whether their use will make risk assessment policy choices more opaque or ...
Poulter, Susan R.
core   +1 more source

Physiologically Based Pharmacokinetic (PBPK) Model-Informed Dosing Guidelines for Pediatric Clinical Care: A Pragmatic Approach for a Special Population. [PDF]

Paediatr Drugs, 2023
Freriksen JJM, van der Heijden JEM, de Hoop-Sommen MA, Greupink R, de Wildt SN.   +4 more
europepmc   +1 more source

Global Sensitivity Analysis of a Physiologically-based Pharmacokinetic (PBPK) Model of Bromochloromethane [PDF]

, 2020
Sawyer, Colton
core   +1 more source

Leveraging Two‐Stage δ Global Sensibility Analysis Method to Inform Parameter Estimation in PBPK Models

Pharmaceutical Statistics, Volume 25, Issue 2, March/April 2026.
ABSTRACT Appropriately performing Global Sensitivity Analysis (GSA) and refining models through the estimation of key parameters on individual data are fundamental steps in PBPK modeling, yet they remain insufficiently addressed in current practice. The main aim of this work is to establish a computational framework linking PhysPK with Python, enabling
Marina Cuquerella‐Gilabert, Alessandro De Carlo, Sergio Sánchez Herrero, Javier Reig‐López, Matilde Merino‐Sanjuan, Elena M. Tosca, Víctor Mangas‐Sanjuan, Paolo Magni   +7 more
wiley   +1 more source

Refinement and calibration of a human PBPK model for the plasticiser, Di-(2-propylheptyl) phthalate (DPHP) using in silico, in vitro and human biomonitoring data. [PDF]

Front Pharmacol, 2023
McNally K, Loizou G.
europepmc   +1 more source

Evaluation of the Effect of Food and Formulation on the Pharmacokinetics of the SHP2 Inhibitor Migoprotafib Within a Phase I Study in Cancer Patients

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT Migoprotafib is a potent and selective inhibitor of Src homology‐2 domain‐containing phosphatase 2 (SHP2) under investigation in Phase I (PhI) trials both as monotherapy and in combination with multiple therapies for patients with metastatic solid tumors.
Julia Suchomel, Christine M. Bowman, Po‐Chang Chiang, Mallika Dhawan, Jennifer Eng‐Wong, Paloma Hauser, Ryan Johnson, Ariel R. Muliadi, Swathi Pisupati, Vidya Ramakrishnan, Leonie Wagner, Sandhya V. Mandlekar   +11 more
wiley   +1 more source

Issue Information

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 4, April 2026.
wiley   +2 more sources

A PBPK model describing the pharmacokinetics of γ-HBCD exposure in mice. [PDF]

Toxicol Appl Pharmacol, 2021
Emond C, DeVito MJ, Birnbaum LS.
europepmc   +1 more source

Comparison of dermal and inhalation routes of entry for organic chemicals [PDF]

The quantitative comparison of the chemical concentration inside the body as the result of a dermal exposure versus an inhalation exposure is useful for assessing human health risks and deciding on an appropriate protective posture.
Clewell, Harvey J., III, Jepson, Gary W., Mcdougal, James N.   +2 more
core   +1 more source

Evaluation of Drug–Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT Zoliflodacin is a first‐in‐class oral spiropyrimidinetrione antibiotic being developed for patients with uncomplicated gonorrhea, including those infected with multidrug‐resistant strains. Because zoliflodacin is metabolized by cytochrome P450 3A4 (CYP3A4), concomitant administration with a CYP3A inhibitor has the potential to increase ...
Alison Luckey, Kajal B. Larson, Noha Rayad, Markus Heep, Sophie Delhomme, Gabrielle Kornmann, John P. Mueller, John P. O'Donnell, Seamus O'Brien, Rainard Fuhr, Jean‐Yves Gillon   +10 more
wiley   +1 more source